Cargando…
Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine
This single-center study included 68 multiple sclerosis (MS) patients who received the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from one of several approved vaccine preparations in Spain. Blood samples were collected one to three months after the second dose of the va...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535818/ https://www.ncbi.nlm.nih.gov/pubmed/37766078 http://dx.doi.org/10.3390/vaccines11091399 |
_version_ | 1785112719428419584 |
---|---|
author | Rodero-Romero, Alexander Sainz de la Maza, Susana Fernández-Velasco, José Ignacio Monreal, Enric Walo-Delgado, Paulette Esperanza Chico-García, Juan Luis Villarrubia, Noelia Rodríguez-Jorge, Fernando Rodríguez-Ramos, Rafael Masjuan, Jaime Costa-Frossard, Lucienne Villar, Luisa María |
author_facet | Rodero-Romero, Alexander Sainz de la Maza, Susana Fernández-Velasco, José Ignacio Monreal, Enric Walo-Delgado, Paulette Esperanza Chico-García, Juan Luis Villarrubia, Noelia Rodríguez-Jorge, Fernando Rodríguez-Ramos, Rafael Masjuan, Jaime Costa-Frossard, Lucienne Villar, Luisa María |
author_sort | Rodero-Romero, Alexander |
collection | PubMed |
description | This single-center study included 68 multiple sclerosis (MS) patients who received the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from one of several approved vaccine preparations in Spain. Blood samples were collected one to three months after the second dose of the vaccine had been administered. Cellular immune responses to the vaccine were assessed using QuantiFERON analysis, and peripheral blood mononuclear cell subsets were assayed using flow cytometry. Response associated with higher percentages of total lymphocytes, naïve CD4+ T-cells (p = 0.028), CD8+ T-cells (p = 0.013), and, mostly, naïve CD8+ T-cells (p = 0.0003). These results were confirmed by analyzing absolute numbers (p = 0.019; p = 0.002, and p = 0.0003, respectively). Naïve CD8 T-cell numbers higher than 17 cells/μL were closely associated with an optimal cellular response to SARS-CoV-2 vaccination (odds ratio: 24.0, confidence interval: 4.8–460.3; p = 0.0001). This finding clearly shows that independent of the treatment received, higher numbers of naïve CD8+ T-cells yield a strong cellular response to SARS-CoV-2 vaccines in MS patients. If this finding is validated with other viruses/vaccines, it could provide a good tool for identifying MS patients undergoing treatment who will develop strong cellular responses to anti-virus vaccines. |
format | Online Article Text |
id | pubmed-10535818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105358182023-09-29 Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine Rodero-Romero, Alexander Sainz de la Maza, Susana Fernández-Velasco, José Ignacio Monreal, Enric Walo-Delgado, Paulette Esperanza Chico-García, Juan Luis Villarrubia, Noelia Rodríguez-Jorge, Fernando Rodríguez-Ramos, Rafael Masjuan, Jaime Costa-Frossard, Lucienne Villar, Luisa María Vaccines (Basel) Article This single-center study included 68 multiple sclerosis (MS) patients who received the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from one of several approved vaccine preparations in Spain. Blood samples were collected one to three months after the second dose of the vaccine had been administered. Cellular immune responses to the vaccine were assessed using QuantiFERON analysis, and peripheral blood mononuclear cell subsets were assayed using flow cytometry. Response associated with higher percentages of total lymphocytes, naïve CD4+ T-cells (p = 0.028), CD8+ T-cells (p = 0.013), and, mostly, naïve CD8+ T-cells (p = 0.0003). These results were confirmed by analyzing absolute numbers (p = 0.019; p = 0.002, and p = 0.0003, respectively). Naïve CD8 T-cell numbers higher than 17 cells/μL were closely associated with an optimal cellular response to SARS-CoV-2 vaccination (odds ratio: 24.0, confidence interval: 4.8–460.3; p = 0.0001). This finding clearly shows that independent of the treatment received, higher numbers of naïve CD8+ T-cells yield a strong cellular response to SARS-CoV-2 vaccines in MS patients. If this finding is validated with other viruses/vaccines, it could provide a good tool for identifying MS patients undergoing treatment who will develop strong cellular responses to anti-virus vaccines. MDPI 2023-08-22 /pmc/articles/PMC10535818/ /pubmed/37766078 http://dx.doi.org/10.3390/vaccines11091399 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rodero-Romero, Alexander Sainz de la Maza, Susana Fernández-Velasco, José Ignacio Monreal, Enric Walo-Delgado, Paulette Esperanza Chico-García, Juan Luis Villarrubia, Noelia Rodríguez-Jorge, Fernando Rodríguez-Ramos, Rafael Masjuan, Jaime Costa-Frossard, Lucienne Villar, Luisa María Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine |
title | Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine |
title_full | Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine |
title_fullStr | Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine |
title_full_unstemmed | Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine |
title_short | Blood CD8+ Naïve T-Cells Identify MS Patients with High Probability of Optimal Cellular Response to SARS-CoV-2 Vaccine |
title_sort | blood cd8+ naïve t-cells identify ms patients with high probability of optimal cellular response to sars-cov-2 vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535818/ https://www.ncbi.nlm.nih.gov/pubmed/37766078 http://dx.doi.org/10.3390/vaccines11091399 |
work_keys_str_mv | AT roderoromeroalexander bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT sainzdelamazasusana bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT fernandezvelascojoseignacio bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT monrealenric bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT walodelgadopauletteesperanza bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT chicogarciajuanluis bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT villarrubianoelia bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT rodriguezjorgefernando bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT rodriguezramosrafael bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT masjuanjaime bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT costafrossardlucienne bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine AT villarluisamaria bloodcd8naivetcellsidentifymspatientswithhighprobabilityofoptimalcellularresponsetosarscov2vaccine |